Core Viewpoint - Avis Budget Group, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 16, 2024, and February 10, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Avis Budget implemented a plan to significantly accelerate its fleet rotation in Q4 2024, which shortened the useful life of most vehicles in the Americas segment [2] - This acceleration is alleged to have led to billions of dollars in impairment charges and substantial losses for the company [2] - The financial and business prospects of Avis Budget were reportedly overstated, and the public statements made by the defendants were materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 24, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Avis Budget Group, Inc. is facing allegations of issuing materially false and misleading statements regarding its fleet rotation plan, which has led to significant financial implications for the company [3][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Avis Budget implemented a plan to significantly accelerate its fleet rotation in Q4 2024, which shortened the useful life of most vehicles in the Americas segment [3]. - This acceleration resulted in the company being forced to recognize billions of dollars in impairment charges and incur substantial losses [3]. - The financial and business prospects of Avis Budget were overstated, leading to a significant negative impact on the company's financial results [3]. Group 2: Class Action Details - The class period for the allegations is from February 16, 2024, to February 10, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline of June 24, 2025, to seek lead plaintiff status [4]. - There is no cost or obligation for shareholders to participate in the case, and they will receive status updates throughout the lifecycle of the case [4].

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR).Shareholders who purchased shares of CAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/avis-budget-loss-submission-form/?id=146178&from=4CLASS PERIOD: February 16, 2024 to ...

Core Viewpoint - A class action has been filed against Avis Budget Group, Inc. for allegedly misleading investors regarding its strategy to accelerate fleet rotations, which led to significant financial losses and impairment charges [1][2]. Group 1: Allegations and Financial Impact - The complaint alleges that Avis Budget failed to disclose a plan to significantly accelerate fleet rotations in Q4 2024, which shortened the useful life of most vehicles in the Americas segment, reducing their recoverable value [2]. - As a result of this strategy, Avis Budget was forced to recognize billions in impairment charges, leading to substantial losses and negatively impacting the company's financial results [2]. - On February 11, 2025, Avis Budget reported a loss of $1.96 billion, or $55.66 per share, for Q4 2024, compared to a profit of $259 million, or $7.10 per share, in the same period the previous year [3]. Group 2: Management Changes and Stock Reaction - The financial results announcement included the resignation of the CEO, with the Chief Transformation Officer set to take over the role [3]. - Following the announcement, Avis Budget's stock price fell by $6.12 per share, nearly 7%, closing at $83.59 per share on February 11, 2025 [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by June 24, 2025 [4]. - Shareholders do not need to participate in the case to be eligible for recovery, and can remain absent class members if they choose [4].

Avis Budget Group (CAR) - Wall Street anticipates a year-over-year decline in earnings for Avis Budget Group, with an expected loss of $5.56 per share, reflecting a -73.2% change, and revenues projected at $2.52 billion, down 1.2% from the previous year [3][12] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook among analysts [4] - The Most Accurate Estimate for Avis Budget is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.54%, suggesting a bearish sentiment among analysts [10][11] Earnings Expectations - The upcoming earnings report is scheduled for May 7, and the stock may react positively if actual results exceed expectations, while a miss could lead to a decline [2] - Historical performance shows that Avis Budget has beaten consensus EPS estimates only once in the last four quarters, with a notable surprise of +76.04% in the last reported quarter [12][13] Comparison with Industry Peers - In contrast, Expeditors International (EXPD) is expected to report earnings of $1.30 per share, indicating a year-over-year increase of +11.1%, with revenues projected at $2.43 billion, up 9.9% from the previous year [17] - Expeditors International has an Earnings ESP of 3.76%, suggesting a higher likelihood of beating the consensus EPS estimate, having surpassed estimates three times in the last four quarters [18]

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Avis Budget Group, Inc. (“Avis Budget” or the “Company”) (NASDAQ:CAR) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Avis Budget securities between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”) ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Avis Budget Group, Inc. ("Avis Budget" or "the Company") (NASDAQ: CAR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ...

Core Insights - March Biosciences has been awarded a $200,000 G-Rex® Grant to advance the manufacturing of its lead asset, MB-105, a novel CAR-T cell therapy targeting CD5 for T-cell lymphomas [1][5]. Company Developments - The grant will support the development of a scalable cGMP process using the G-Rex bioreactor, aimed at reducing complexity, time, and costs in manufacturing autologous CAR-T products [2][4]. - March Biosciences is focused on overcoming scalability and efficiency barriers in the manufacturing of MB-105, with the support of Wilson Wolf Manufacturing [3][5]. - The G-Rex Grant will facilitate the establishment of a fully integrated CAR-T cell manufacturing process, enhancing the production capabilities for MB-105 and other CAR-T products in development [4][6]. Industry Context - The G-Rex Grant Program, which has awarded nearly 200 grants, aims to advance cell and gene-modified cell therapy (CGT) development and manufacturing, with individual grants worth up to $300,000 [6][8]. - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, indicating its significant role in the industry [8]. - March Biosciences' MB-105 has received U.S. FDA orphan drug designation for treating relapsed/refractory CD5-positive T-cell lymphoma, highlighting its potential in addressing unmet medical needs [5][14].

Core Viewpoint - A class action lawsuit has been filed against Avis Budget Group, Inc. for allegedly misleading investors regarding its strategy to accelerate fleet rotations, which led to significant financial losses and impairment charges [1][2]. Summary by Sections Allegations - Robbins LLP is investigating claims that Avis Budget failed to disclose a plan to significantly accelerate fleet rotations in Q4 2024, which shortened the useful life of most vehicles in the Americas segment, reducing their recoverable value [2]. - The company is expected to recognize billions in impairment charges and incur substantial losses, negatively impacting its financial results and overstating its business prospects [2]. Financial Results - On February 11, 2025, Avis Budget reported disappointing financial results for Q4 and full year 2024, including a loss of $1.96 billion, or $55.66 per share, compared to a profit of $259 million, or $7.10 per share, in the same period the previous year [3]. - The loss was attributed to a change in strategy that resulted in a one-time non-cash impairment of $2.3 billion and additional non-cash charges of $180 million [3]. - Following the announcement, Avis Budget's stock price fell by $6.12 per share, nearly 7%, closing at $83.59 per share [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by June 24, 2025, but participation is not required to be eligible for recovery [4].

Core Viewpoint - A class action lawsuit has been filed against Avis Budget Group, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 16, 2024, to February 10, 2025, seeking damages for misleading statements regarding the company's business and operations [1][6]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey, representing all individuals and entities that purchased Avis Budget securities during the specified Class Period [1]. - Investors have until June 24, 2025, to request appointment as Lead Plaintiff for the class [2]. Group 2: Company Overview - Avis Budget Group provides car and truck rentals, car sharing, and ancillary services globally, operating brands such as Avis, Zipcar, and Budget, with a global rental fleet of approximately 695,000 vehicles in 2024 [3]. Group 3: Fleet Management and Strategy - Effective fleet management is crucial for Avis Budget's profitability, involving proper fleet rotation to avoid depreciation and high maintenance costs [4]. - Following the Covid-19 pandemic, Avis Budget slowed its fleet rotation due to higher vehicle prices, which allowed for better depreciation management [5]. - In Q4 2024, Avis Budget accelerated fleet rotations to adapt to normalizing vehicle prices, which led to a significant impairment charge and reduced the recoverable value of many vehicles [5][6]. Group 4: Financial Impact - Avis Budget reported a loss of $1.96 billion, or $55.66 per share, for Q4 2024, attributed to a one-time non-cash impairment of $2.3 billion and other charges [7]. - The company's CEO announced a transition to a Board Advisor role, with a new CEO taking over in July 2025, following the financial report [7]. Group 5: Market Reaction - Following the announcement of the financial results and the impairment charge, Avis Budget's stock price fell by $6.12 per share, or 6.82%, closing at $83.59 per share on February 11, 2025 [7].